Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

Summary

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic breast cancer. Imatinib mesylate may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth

Timeline

Start

2002-08

Primary completion

2004-07

Completion

—

Drugs

Indications